Coley Pharmaceutical Group Updates Hepatitis C Drug Development Strategy
Tue, 23 Jan 2007 08:00 AM EST
... Coley Pharmaceutical Group, Inc. (Nasdaq: COLY) today announced that the company has made the strategic decision to suspend the independent development of ACTILON, its product candidate for the treatment of Hepatitis C virus (HCV) infection. [click link for full article] ...
Related Topics
- Hepatitis C
- Hepatitis B
- Child Development
- Fetal Development
- Hepatitis A
- Drug Information
- Teen Development
- Community Development
- Hepatitis
- Hepatitis A and Hepatitis B Vaccine
- Hepatitis A Vaccine
- Hepatitis B Vaccine
- Autoimmune Hepatitis
- Drug Safety
- Prescription Drugs
- Infant and Toddler Development
- Support Groups
- Universal Data Collection Updates
- Research Updates in Kidney and Urologic Health
- Drug Side Effects

Not Signed In -


